Posts

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

on

ADC Therapeutics shares sink over 50% after Phase 3 Zynlonta trial shows more deaths than standard therapy

on

Sarepta Therapeutics Reports Positive Three-Year EMBARK Data for Elevidys in Duchenne Amid Past Safety Concerns

on

Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths

on

Untangling Sarepta's Gene Therapy Fallout and Trust Deficit

on

Roche Halts Elevidys Distribution in Several Countries Following Sarepta and FDA Safety Concerns

on

Lack of Transparency Tarnishes Sarepta's Sheen as Patient Deaths Trigger FDA Battle

on

Sarepta Halts US Shipments of Duchenne Therapy Elevidys After FDA Pressure

on

Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys

on

FDA Threatens Action After Sarepta Refuses to Halt Elevidys Shipments

on

Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments

on

FDA Investigates Patient Deaths Linked to Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy

on